Bio Green Med Solution (BGMS)
NASDAQ:BGMS
BGMS Stock Chart & Stats
$1.45
--
Market closed
$1.45
--
Day’s Range― - ―
52-Week Range$0.73 - $100.67
Previous CloseN/A
VolumeN/A
Average Volume (3M)473.94K
Market Cap
$4.82M
Enterprise Value-$1.92M
Total Cash (Recent Filing)$3.84M
Total Debt (Recent Filing)$5.00K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.27%
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,900,142
10 Day Avg. Volume1,252,948
30 Day Avg. Volume473,939
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)3.12
P/FCF Ratio-0.02
Enterprise Value/Market Cap-0.40
Enterprise Value/Revenue-23.75
Enterprise Value/Gross Profit-120.23
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Reduction In R&D ExpensesReducing R&D expenses through the liquidation of a subsidiary can improve financial stability, allowing Cyclacel to allocate resources more efficiently towards core projects.
Leadership And RestructuringThe new leadership under Dr. Doris Wong Sing Ee and restructuring efforts may enhance strategic direction and operational efficiency, improving long-term business prospects.
Strategic Focus On PLK1 InhibitorCyclacel's focus on plogosertib, a PLK1 inhibitor, aligns with its expertise in cancer therapies, potentially leading to innovative treatments and future revenue streams.
Bears Say
Operational InefficienciesNegative EBIT and EBITDA margins reflect operational inefficiencies, which can hinder Cyclacel's profitability and long-term sustainability in a competitive biotech industry.
Negative Cash FlowsNegative free cash flow highlights challenges in generating cash from operations, which can strain Cyclacel's ability to fund development projects and meet financial obligations.
Financial InstabilityNegative stockholders' equity and high leverage indicate financial instability, which can limit Cyclacel's ability to invest in growth and weather economic downturns.
Bio Green Med Solution News
BGMS FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was $0.73 and its highest was $100.67 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is $4.82M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is May 13, 2026 which is in 48 days.
How were Bio Green Med Solution’s earnings last quarter?
Currently, no data Available
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution pays a Notavailable dividend of $0.15 which represents an annual dividend yield of 10.27%. See more information on Bio Green Med Solution dividends here
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 4,900,142 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in BGMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―
Ownership Overview
64.26% Insiders
<0.01% Mutual Funds
1.08% Other Institutional Investors
34.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---